Thank you those who responded to this thread. I know there is an ongoing debate whether CFS / ME has autoimmune etiology vs chronic infection. I think CFS / ME is a heterogeneous disease and there isn't enough information to discern a clear pattern at this time.
I recently came across a fairly recent review article in the journal of Virology.
http://www.sciencedirect.com/science/article/pii/S0042682215002834
I have read some postulate that Rituximab responders may be those who are infected with EBV in B cells. However, there may be another subset whose symptoms were triggered by an enterovirus. My acute illness occurred in early summer of 2012 with prominent autonomic dysfunction and muscle symptoms.
Here is an excerpt from the article listed above that I found very interesting:
"Recent studies have shown the clinical dangers of suppressing the humoral immune response with anti-CD20 monoclonal antibodies such as rituximab. Treatment with rituximab is routinely given to patients suffering from lymphomas, leukemias, transplant rejection and some autoimmune disorders. However, case reports describing EV meningoencephalitis following treatment with rituximab have been increasing in number (
Servais et al., 2010 and
Schilthuizen et al., 2010). B cell-dependent immunosuppression following the administration rituximab as a therapy for lymphomas or leukemias would naturally reduce the level of circulating anti-CVB antibodies. If these protective antibodies suppress CVB replication in target tissues such as the CNS harboring persistent viral RNA, meningoencephalitis might be the outcome for some patients (
Kiani-Alikhan et al., 2009)."
I am not trying to make a case for or against treatment with Rituximab. My opinion is that we do not have enough data from a sufficiently powered study to draw conclusions for all CFS/ME patients.
I suspect there is increased research interest in Coxsackie virus due to cases of childhood paralysis from an enterovirus over the last 2 years.
@Jonathan Edwards
@Hip